A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Protocol: 
AAAR3867
Phase: 
I

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

The main purpose of this study is learn about the the safety and side effects
of the study drug, RGX-104. RGX-104 is an experimental drug. This means that
RGX-104 is not approved by the Food and Drug Administration (FDA). This is the
first time RGX-104 will be given to humans.

Are you Eligible? (Inclusion Criteria)

- Do you have a confirmed solid tumor?

- Have you had treatment for your disease before? Or is there not a standard
treatment available for your disease?

- Does your cancer continue to grow? Can your cancer not be removed by
surgery?

- Are you 18 years of age or older?

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States